SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

European Journal of Pharmacology
Warren D HirstNeil Upton


SB-399885 (N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide) has high affinity for human recombinant and native 5-HT(6) receptors, with pK(i) values 9.11+/-0.03 and 9.02+/-0.05, respectively and is a potent competitive antagonist (pA(2) 7.85+/-0.04). It displays over 200-fold selectivity for the 5-HT(6) receptor over all other receptors, ion channels and enzymes tested to date. SB-399885 inhibited ex vivo [(125)I]SB-258585 (4-Iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzenesulfonamide) binding with an ED(50) of 2.0+/-0.24 mg/kg p.o. in rats. It had a minimum effective dose of 1 mg/kg p.o. in a rat maximal electroshock seizure threshold test and a long duration of action, overall demonstrating an excellent pharmacokinetic-pharmacodynamic correlation. Repeated administration of this agent (10 mg/kg p.o., b.i.d. for 7 days) significantly reversed a scopolamine-induced deficit (0.5 mg/kg i.p.) in a rat novel object recognition paradigm. Moreover, in aged rats (22 months old) SB-399885 (10 mg/kg p.o., b.i.d. for 7 days) fully reversed the age-dependent deficit in water maze spatial learning compared to vehicle-treated age-matched controls and significantly improved recall of the task me...Continue Reading


Apr 23, 2005·Psychopharmacology·Paula D HatcherDeclan N C Jones
May 23, 2009·Psychopharmacology·Hugh M MarstonMohammed Shahid
Nov 11, 2009·Psychopharmacology·Katherine E BurnhamTrevor Sharp
Mar 11, 2010·Psychopharmacology·Gregory V CarrIrwin Lucki
Oct 27, 2012·Biogerontology·Sara FidalgoShona H Wood
Jul 31, 2013·Neuropharmacology·R AnandAbbas Ali Mahdi
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Jul 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Virginie Da Silva CostaFrançois Dauphin
Dec 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua S RodeferJørn Arnt
Oct 3, 2008·Neuropsychiatric Disease and Treatment·J D Best, Wendy K Alderton
Nov 16, 2013·Experimental Brain Research·Mohammad Hadi GharedaghiReza Rahimian
Oct 3, 2012·EMBO Molecular Medicine·Julie MeffrePhilippe Marin
Jun 7, 2014·Pharmacological Reports : PR·Renny AbrahamAnil Shinde
Aug 23, 2008·Drug Development and Industrial Pharmacy·James C DiNunzio, Robert O Williams
Nov 10, 2015·Expert Opinion on Investigational Drugs·Karsten WickeAnton Bespalov
May 3, 2011·Expert Opinion on Drug Discovery·Altaf S DarveshCornelis J Van der Schyf
Jan 29, 2011·Pharmacological Reports : PR·Katarzyna FijałMałgorzata Filip
Oct 23, 2013·Pharmacological Reports : PR·Magdalena Jastrzębska-WięsekAnna Wesołowska
Jul 7, 2012·Progress in Neurobiology·José Julio RodríguezAlexei Verkhratsky
Sep 8, 2011·Neuroscience Letters·Kazufumi HiranoA Richard Rutter
Mar 23, 2011·Pharmacology, Biochemistry, and Behavior·Segev Barak, Ina Weiner
Feb 15, 2011·Pharmacology, Biochemistry, and Behavior·Alvin V TerryScott J Webster
Feb 19, 2011·Current Opinion in Pharmacology·Xabier CodonyMaria Javier Ramírez
Dec 28, 2010·Neuropharmacology·V ValentiniG Di Chiara
Apr 24, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jan KehrSven Ove Ogren
Jan 2, 2010·Behavioural Brain Research·Trisha A JenkinsStephen J Cooper


Nov 1, 1988·Behavioural Brain Research·A Ennaceur, J Delacour
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 7, 1993·Nature·T V Bliss, G L Collingridge
Dec 1, 1995·Trends in Pharmacological Sciences·W P Bowen, J C Jerman
Feb 13, 2001·Behavioural Brain Research·Alfredo Meneses
Nov 10, 2001·Psychopharmacology·Derek C Rogers, Jim J Hagan
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Daniel HoyerGraeme R Martin
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Mark D LindnerValentin K Gribkoff
Oct 23, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrew G FoleyCiaran M Regan
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cindy K J LiebenRudy Schreiber

Related Concepts

Neuro-Oncological Ventral Antigen 2
Serotonin 6 receptor
Dialysis Solutions
Tissue Membrane
Adrenal Cortex Diseases
Hydrogen Peroxide
Benign Mixed Epithelial and Stromal Tumor of Kidney
Body Parts - Cannula

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.